Valeant Pharmaceuticals Intl Inc.: The Plan for 2016

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will look very different in 2016.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) interim CEO Howard Schiller gave his first public presentation Wednesday in San Francisco. We’ll look at the three biggest takeaways and what they mean for Valeant going forward.

1. The Walgreens deal

Valeant announced a new 20-year distribution agreement with Walgreens Boots Alliance Inc. in December, which will see many of its products sold at discounted prices.

The first phase of the program, which consists of Valeant’s dermatology products, will start on Friday. Addyi (better-known as the “female Viagra”) and ophthalmology products will follow shortly thereafter. The final phase, which consists of the Valeant drugs most exposed to generic competition, will begin in the middle of this year.

Interestingly, the Walgreens partnership will help Valeant break even this year. And while the program should become more profitable down the road, it does mark a significant shift for Valeant from years past.

2. Scaling back

Even before Wednesday Valeant had committed to shifting its strategy. Gone are the days of big acquisitions, big increases in debt, and dramatic price increases. Instead Valeant will devote the lion’s share of free cash flow–roughly US$2.25 billion–towards paying down debt.

And on Wednesday we even heard that Valeant may sell some assets. This would be a remarkable shift from Valeant’s strategy just a year ago.

It should also raise some concerns. Remember, the main argument from Valeant bears (before the current controversies surfaced) was that the company is a rollup. In other words, Valeant relies on acquisitions to cover up its fundamental problems. So once these acquisitions stop, we’ll see Valeant for what it really is.

Valeant investors better hope these bears are wrong.

3. No new updates

Valeant was facing a number of issues at the end of last year. Tops among them is what exactly happened at Philidor. There is also the big question about Michael Pearson’s health. And of course there are a litany of outside investigations into the company’s practices. Valeant provided no new updates on any of these matters, which is certainly a disappointment.

On the bright side, the company did reaffirm its guidance for this year. Those numbers were deemed very positive when originally announced, so we’ll have to wait and see if Valeant can meet them.

Without a doubt, this is a “put up or shut up” year for Valeant. So the stock will likely move very sharply as the year progresses. We’ll just have to wait and see which direction it will go.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Question marks in a pile
Bank Stocks

Should You Buy Canadian Western Bank for its 4.8% Dividend Yield?

Down 35% from all-time highs, Canadian Western Bank offers a tasty dividend yield of 4.8%. Is the TSX bank stock…

Read more »

Gold bars
Metals and Mining Stocks

Why Alamos Gold Jumped 7% on Wednesday

Alamos (TSX:AGI) stock and Argonaut Gold (TSX:AR) surged after the companies announced a friendly acquisition for $325 million.

Read more »

tsx today
Stock Market

TSX Today: Why Record-Breaking Rally Could Extend on Thursday, March 28

The main TSX index closed above the 22,000 level for the first time yesterday and remains on track to post…

Read more »

Nuclear power station cooling tower
Metals and Mining Stocks

If You’d Invested $1,000 in Cameco Stock 5 Years Ago, This Is How Much You’d Have Now

Cameco (TSX:CCO) stock still looks undervalued, despite a 258% rally. Can the uranium miner deliver more capital gains to shareholders?

Read more »

Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept
Dividend Stocks

TFSA Magic: Earn Enormous Passive Income That the CRA Can’t Touch

If you're seeking out passive income, with zero taxes involved, then get on board with a TFSA and this portfolio…

Read more »

potted green plant grows up in arrow shape
Stocks for Beginners

3 Growth Stocks I’m Buying in April

These three growth stocks are up in the last year, and that is likely to continue on as we keep…

Read more »

clock time
Tech Stocks

Long-Term Investing: 3 Top Canadian Stocks You Can Buy for Under $20 a Share

These three under-$20 stocks offer excellent buying opportunities for long-term investors.

Read more »

Man with no money. Businessman holding empty wallet
Dividend Stocks

2 Stocks Under $50 New Investors Can Confidently Buy

There are some great stocks under $50 that every investor needs to know about. Here’s a look at two great…

Read more »